Curis (NASDAQ:CRIS) Posts Earnings Results, Misses Estimates By $0.02 EPS

Curis (NASDAQ:CRISGet Rating) released its quarterly earnings results on Thursday. The biotechnology company reported ($0.18) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.16) by ($0.02), MarketWatch Earnings reports. Curis had a negative net margin of 426.67% and a negative return on equity of 42.46%. During the same quarter in the prior year, the business earned ($0.11) EPS.

NASDAQ:CRIS traded down $0.04 during mid-day trading on Friday, hitting $0.88. 1,705,004 shares of the stock traded hands, compared to its average volume of 1,522,605. The business’s 50-day moving average price is $1.98 and its 200 day moving average price is $3.66. The company has a market cap of $80.19 million, a PE ratio of -1.54 and a beta of 3.15. Curis has a 12-month low of $0.85 and a 12-month high of $17.40.

A number of research analysts recently weighed in on CRIS shares. Raymond James lowered shares of Curis from an “outperform” rating to a “market perform” rating and set a $15.00 price target on the stock. in a research report on Monday, April 4th. Zacks Investment Research upgraded shares of Curis from a “sell” rating to a “hold” rating in a report on Monday, May 2nd. StockNews.com assumed coverage on shares of Curis in a report on Thursday, March 31st. They set a “sell” rating for the company. B. Riley decreased their price objective on shares of Curis from $22.00 to $10.00 and set a “buy” rating for the company in a report on Tuesday, April 5th. Finally, Cantor Fitzgerald decreased their price objective on shares of Curis from $12.00 to $4.00 in a report on Tuesday, April 5th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and three have given a buy rating to the company. Based on data from MarketBeat, Curis presently has a consensus rating of “Hold” and a consensus target price of $10.85.

A number of institutional investors have recently made changes to their positions in CRIS. Millennium Management LLC lifted its position in Curis by 2,477.8% during the fourth quarter. Millennium Management LLC now owns 2,005,163 shares of the biotechnology company’s stock valued at $9,545,000 after purchasing an additional 1,927,376 shares during the last quarter. BlackRock Inc. lifted its position in Curis by 10.0% during the fourth quarter. BlackRock Inc. now owns 6,281,041 shares of the biotechnology company’s stock valued at $29,899,000 after purchasing an additional 569,846 shares during the last quarter. Schonfeld Strategic Advisors LLC lifted its position in Curis by 606.4% during the fourth quarter. Schonfeld Strategic Advisors LLC now owns 511,467 shares of the biotechnology company’s stock valued at $2,434,000 after purchasing an additional 439,067 shares during the last quarter. Renaissance Technologies LLC bought a new stake in Curis during the fourth quarter valued at approximately $2,080,000. Finally, UBS Group AG lifted its position in Curis by 14,853.0% during the third quarter. UBS Group AG now owns 356,032 shares of the biotechnology company’s stock valued at $2,787,000 after purchasing an additional 353,651 shares during the last quarter. Institutional investors and hedge funds own 78.15% of the company’s stock.

Curis Company Profile (Get Rating)

Curis, Inc, a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small molecule drug candidate, which is in a Phase 1/2 clinical trial for the treatment of non-hodgkin lymphomas, and acute myeloid leukemia and myelodysplastic syndromes; and CI-8993, a monoclonal antibody designed to antagonize the V-domain Ig suppressor of T cell activation.

Featured Articles

Earnings History for Curis (NASDAQ:CRIS)

Receive News & Ratings for Curis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Curis and related companies with MarketBeat.com's FREE daily email newsletter.